Your session is about to expire
← Back to Search
Enoblituzumab for Prostate Cancer
Study Summary
This trial will test a new drug, Enoblituzumab, to see if it is safe and effective against prostate cancer. Patients will receive the drug for 6 weeks before surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 trial • 3 Patients • NCT04630769Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the cap on participants in this research trial?
"This research project has concluded its recruitment phase. It was initially advertised on February 14th 2017 and last modified on December 7th 2022. Nevertheless, there are presently 1326 clinical trials searching for prostate cancer patients and one seeking volunteers to test Enoblituzumab."
Have there been any other investigations into the effects of Enoblituzumab?
"Currently, there is one active research project investigating enoblituzumab and it has yet to reach Phase 3. While most of the trials for this drug are being performed in Baltimore, Maryland, a single other medical centre also offers testing with this medication."
What are the main goals of this clinical experimentation?
"During this two year trial, the primary focus is to assess neoadjuvant enoblituzumab's efficacy through PSA0 response rate. Secondary objectives include evaluating participants' pathological complete responses (pCR) and Gleason Grade Group Change as well as quantifying markers of apoptosis in prostate tumor specimens of treated patients via TUNEL staining."
Has Enoblituzumab earned endorsement from the FDA?
"This Phase 2 trial has generated some evidence indicating Enoblituzumab's safety, thus garnering a score of 2. Nonetheless, there is still no empirical proof that this medication can be effective at treating its respective conditions."
Are there any current openings for participation in this experiment?
"As reported on clinicaltrials.gov, this specific trial has concluded its recruitment phase and is no longer looking for individuals to participate. This study was first announced in February 2017 with the last modification being made in December 2022; however, 1327 other trials are still actively seeking participants at this time."
Is this research a pioneering venture?
"Currently, there is an active clinical trial for enoblituzumab running in 1 city and 1 nation. This drug was initially tested back in 2017 by MacroGenics with 33 participants concluding its Phase 2 trials. Since then, 5 studies have been concluded."
Share this study with friends
Copy Link
Messenger